Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| MADRIGAL PHARMACEUTICALS, INC.MDGL · Entity 3441 | SVP and General Counsel | January 23, 2024 | January 25, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
MADRIGAL PHARMACEUTICALS, INC.
Report date January 23, 2024 · Filed January 25, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 17,691 |
Reported balance
After 2024-01-23 transaction · row 1
1 source rowRow 1 · 2024-01-23 · Grant · Acquired 3,639 · Balance 17,691 F1: Represents a grant of restricted stock units, which vest as to 25% of the shares on each of January 23, 2025, January 23, 2026, January 23, 2027 and January 23, 2028, provided the Reporting Person continues in service with the Issuer on each such date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $229.00 · Expires 2031-01-23 | Direct | 5,483 |
Reported balance
After 2024-01-23 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2024-01-23 · Grant · Acquired 5,483 · Balance 5,483 F2: The option vests as to 25% of the shares on the first anniversary of the date of grant (January 23, 2025) and, thereafter, 6.25% of the shares shall vest on the last day of each successive three month period, provided the Reporting Person continues in service with the Issuer on each such date. |
| Market Stock UnitSEC Table II · derivative / convertible security | Direct | 3,639 |
Reported balance
After 2024-01-23 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2024-01-23 · Grant · Acquired 3,639 · Balance 3,639 F3: Each market stock unit, which is performance-based, represents the contingent right to receive one share of common stock. The amount reported represents the target number of shares which may be issued upon vesting. The market stock units will vest upon certification concerning the Company's stock price performance measured against biotechnology stock index companies for the entire performance period ending December 31, 2026. |
| Common StockSEC Table I · non-derivative | IndirectIn IRA | 530 |
Reported balance
Holding disclosure · report date 2024-01-23 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 530 |
Filing footnotes · ownership attribution and instrument terms
F1: Represents a grant of restricted stock units, which vest as to 25% of the shares on each of January 23, 2025, January 23, 2026, January 23, 2027 and January 23, 2028, provided the Reporting Person continues in service with the Issuer on each such date.
F2: The option vests as to 25% of the shares on the first anniversary of the date of grant (January 23, 2025) and, thereafter, 6.25% of the shares shall vest on the last day of each successive three month period, provided the Reporting Person continues in service with the Issuer on each such date.
F3: Each market stock unit, which is performance-based, represents the contingent right to receive one share of common stock. The amount reported represents the target number of shares which may be issued upon vesting. The market stock units will vest upon certification concerning the Company's stock price performance measured against biotechnology stock index companies for the entire performance period ending December 31, 2026.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 23, 2022 Filed Dec 29, 2022 01:00 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | Exercise / conversionCommon Stock | 7,000 | $91.79 | $642,530.00 |
DisclosureSEC source: 0000899243-22-039464 · doc4.xml · nonDerivative · entry 1 Lynch Brian Joseph · CIK 0001776196 · SVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: All transactions reported herein were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| August 10, 2022 Filed Aug 12, 2022 20:30 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | GrantStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $73.75 | $0.00 |
DisclosureSEC source: 0000899243-22-028491 · doc4.xml · derivative · entry 1 Lynch Brian Joseph · CIK 0001776196 · SVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2032-08-10 F1 · derivative.exercise_date: The option vests as to 25% of the shares on the first anniversary of the date of grant (08/10/2023) and, thereafter, 6.25% of the shares shall vest on the last day of each successive three month period, provided the Reporting Person continues in service with the Issuer on each such date. Read SEC document |
| February 22, 2022 Filed Feb 25, 2022 01:18 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | GrantStock Option (Right to Buy) · Derivative | 45,000 | $0.00 Strike: $87.09 | $0.00 |
DisclosureSEC source: 0000899243-22-007776 · doc4.xml · derivative · entry 1 Lynch Brian Joseph · CIK 0001776196 · SVP and General Councel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Stock · 45,000 shares Expires 2032-02-22 F1 · derivative.exercise_date: The option vests as to 25% of the shares on the first anniversary of the date of grant (02/22/2023) and, thereafter, 6.25% of the shares shall vest on the last day of each successive three month period, provided the Reporting Person continues in service with the Issuer on each such date. Read SEC document |
| February 22, 2021 Filed Feb 23, 2021 18:29 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | GrantStock Option (Right to Buy) · Derivative | 32,000 | $0.00 Strike: $119.49 | $0.00 |
DisclosureSEC source: 0000899243-21-007759 · doc4.xml · derivative · entry 1 Lynch Brian Joseph · CIK 0001776196 · SVP and General Councel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,000 Underlying: Common Stock · 32,000 shares Expires 2031-02-22 F1 · derivative.exercise_date: The option vests as to 25% of the shares on the first anniversary of the date of grant (02/22/2022) and, thereafter, 6.25% of the shares shall vest on the last day of each successive three month period, provided the Reporting Person continues in service with the Issuer on each such date. Read SEC document |
| August 06, 2020 Filed Aug 10, 2020 23:07 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | GrantStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $103.10 | $0.00 |
DisclosureSEC source: 0000899243-20-021949 · doc4.xml · derivative · entry 1 Lynch Brian Joseph · CIK 0001776196 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2030-08-06 F1 · derivative.exercise_date: The option vests as to 25% of the shares on the first anniversary of the date of grant (August 6, 2021) and, thereafter, 6.25% of the shares shall vest on the last day of each successive three month period, provided the Reporting Person continues in service with the Issuer on each such date. Read SEC document |
| March 05, 2020 Filed Mar 5, 2020 22:05 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | GrantStock Option (Right to Buy) · Derivative | 32,000 | $0.00 Strike: $91.79 | $0.00 |
DisclosureSEC source: 0000899243-20-007223 · doc4.xml · derivative · entry 1 Lynch Brian Joseph · CIK 0001776196 · SVP and General Councel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,000 Underlying: Common Stock · 32,000 shares Expires 2030-03-05 F1 · derivative.exercise_date: The option vests as to 25% of the shares on the first anniversary of the date of grant (March 5, 2021) and, thereafter, 6.25% of the shares shall vest on the last day of each successive three month period, provided the Reporting Person continues in service with the Issuer on each such date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.